《港湾商业观察》施子夫 王璐近期,劲方医药科技(上海)股份有限公司(以下简称,劲方医药)向港交所递交招股书,拟通过18A规则于港股主板上市,独家保荐人为中信证券。这已经是劲方医药二度递表。2024年12月27日公司首度递表,其后宣告失效。虽然公司收入不断增加,但迄今仍未脱离亏损窘境,此外,公司现金流连年为负,且负债率超过400%。1两年多亏损超12亿,今年将减少招股书及天眼查显示,劲方医药成立于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.